Protocol Ledger

NCT06564324 · Phase III · RECRUITING

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Interventional Phase III clinical trial protocol NCT06564324 sponsored by Nuvation Bio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-27 Enrollment: 194 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06564324
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06564324
Protocol FieldVerified Registry Value
NCT IdentifierNCT06564324
Consolidated Lead SponsorNuvation Bio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment194 participants (ESTIMATED)
Registered Start Date2024-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI